Axitinib (Inlyta) falls under the small molecule tyrosine kinase inhibitor (TKI) developed by Pfizer. It has been demonstrated in order to inhibit the breast cancer growth in xenograft models and has shown partial responses in the clinical trials with RCC (Renal Cell Carcinoma) and several other tumour types.
In the month of July, 2011, Pfizer filed with the Food and Drug Administration for the review of axitinib in order to treat patients with the advanced Renal Cell Carcinoma.
In the month of December, 2011, the Food and Drug Administration advisory committee finds the benefit or risk profile of the axitinib in the previously treated patients with advanced Renal Cell Carcinoma (RCC) to be favorable.
In the month of January, 2012, the Food and Drug Administration approved axitinib 5 mg for theAxitinib a treatment of advanced RCC (Renal Cell Carcinoma).
In the month of April, 2019, pembrolizumab together with axitinib was approved by the Food and Drug Administration as a first-line therapy in order to treat patients with the advanced RCC (Renal Cell Carcinoma).
In the month of May, 2019, the Food and Drug Administration approved a combination of avelumab plus axitinib in order to treat patients with advanced Renal Cell Carcinoma.
The axitinib price in India is around 3,735 INR for a supply of 14 tablets, depending on the wholesaler/pharmacy you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy Axitinib.
